China SXT Pharmaceuticals, Inc.
SXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001723980
No open-market purchases or sales by China SXT Pharmaceuticals, Inc. insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $6 in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding China SXT Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 7 | 7 | 0 |
| Shares | 73.4K | 46.9K | −26.5K (−36.1%) |
| Value | $79.9K | $30.0K | −$50.0K (−62.5%) |
New holders (3)
Institutions that held China SXT Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 12,300 | $9.00K | 0.00% |
| Baader Bank INC | 15,161 | $7.93K | 0.00% |
| JPMorgan Chase & Co | 376 | $274 | 0.00% |
Sold out (3)
Institutions that held China SXT Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Virtu Financial LLC | 31,607 | $34.0K |
| Citadel Advisors LLC | 16,115 | $17.4K |
| Qube Research & Technologies Ltd | 303 | $327 |